Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis

Vertex’s renal pipeline is a major near-term focus. Data from the AMPLIFIED Phase II study of inaxaplin is expected in the coming months, while a Phase III interim analysis is planned for the first quarter of 2027. The company also has a Nov. 30, 2026, PDUFA date for povetacicept in IgA nephropathy. JOURNAVX is expanding commercially and clinically. Vertex expects prescriptions for the acute-pain drug to triple in 2026 versus 2025, supported by broader reimbursement, a larger sales force and more than 36,000 prescribers. Phase III diabetic peripheral neuropathy data could arrive in the first half of 2027. Vertex is broadening beyond cystic fibrosis through acquisitions and pipeline updates. The completed Crinetics acquisition adds PALSONIFY and atumelnant, which Vertex estimates could generate roughly $5 billion in peak sales, while additional catalysts include VX-522, myotonic dystrophy and povetacicept studies in myasthenia gravis.

Vertex Pharmaceuticals NASDAQ: VRTX highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a Wells Fargo healthcare conference appearance. Susie Lisa, the company’s head of investor relations, said investor discussions have increasingly focused on Vertex’s expanding pipeline beyond cystic fibrosis, particularly its renal franchise. She described the coming period as “catalyst-rich,” with data updates expected in several programs through 2027.

The nearest expected catalyst is data in the coming months from the AMPLIFIED Phase II proof-of-concept study of inaxaplin in APOL1-mediated kidney disease. The study includes patients with two APOL1 variants in cohorts with more moderate proteinuria and with type 2 diabetes. Lisa said the moderate-proteinuria cohort could help demonstrate the effect of APOL1 inhibition beyond patients with focal segmental glomerulosclerosis, or FSGS. Vertex previously reported results from the Phase II portion of its pivotal program in a population that included patients with high proteinuria burdens, showing a 47.6% reduction in proteinuria at 13 weeks, according to Lisa.

She noted that the diabetes cohort presents more uncertainty because Vertex will need to assess how much of patients’ kidney impairment is associated with APOL1-mediated disease versus type 2 diabetes. The AMPLIFIED cohorts each include more than 20 patients, she said. Vertex estimates that its pivotal AMPLITUDE study population could represent approximately 150,000 patients in the U.S. and Europe. Expansion into the populations being evaluated in AMPLIFIED could add roughly 100,000 patients to the target population, Lisa said.

The company expects a Phase III interim analysis for inaxaplin in the first quarter of 2027. The 48-week analysis will evaluate change in estimated glomerular filtration rate, or eGFR, from baseline as well as proteinuria reduction. Lisa said a successful interim analysis could support a filing path while patients continue to be followed through the full two-year endpoint.

Vertex also cited a Nov. 30, 2026, PDUFA date for povetacicept in immunoglobulin A nephropathy, or IgAN. Lisa said the company is launch-ready, with a sales force already hired that includes substantial nephrology experience. For a potential IgAN launch, Vertex plans to emphasize what Lisa described as the therapy’s clinical data, safety profile a...